PARP Archives -

Optimize PARP inhibitors in the clinic

PARP & DDR Inhibitors Summit 2021

https://pharmaphorum.com/events/parp-ddr-inhibitors-summit-2021/

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

https://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/

Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced

Merck and Pfizer stop third Bavencio ovarian cancer trial

https://pharmaphorum.com/news/merck-and-pfizer-stop-third-bavencio-ovarian-cancer-trial/

GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its

GSK enters PARP space with TESARO acquisition

https://pharmaphorum.com/news/gsk-enters-parp-space-with-tesaro-acquisition/

PARP